{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:40:17Z","timestamp":1782441617168,"version":"3.54.5"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taisho Toyama Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sumitomo Dainippon Pharma Co., Ltd."},{"DOI":"10.13039\/501100005612","name":"Shionogi & Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Miyarisan Pharmaceutical Co. Ltd."},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujifilm Pharma Co., Ltd"},{"name":"Toyama Chemical Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jiac.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:56:42Z","timestamp":1544057802000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8767","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Monden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Shizuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2018.10.012_bib1","article-title":"Guidance for Industry-Complicated Intra-Abdominal Infections: Developing Drugs for Treatment","year":"2015","journal-title":"Clin Antimicrob"},{"key":"10.1016\/j.jiac.2018.10.012_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.surg.2009.06.051","article-title":"Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection","volume":"146","author":"Inui","year":"2009","journal-title":"Surgery"},{"key":"10.1016\/j.jiac.2018.10.012_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/2047-783X-15-12-525","article-title":"Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria","volume":"15","author":"Herzog","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jiac.2018.10.012_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2125.2005.02443.x","article-title":"Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs","volume":"60","author":"Sturkenboom","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2018.10.012_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.10.012_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/109629600321308","article-title":"The role of \u03b2-lactam antimicrobials as single agents in treatment of intra-abdominal infection","volume":"1","author":"Powell","year":"2000","journal-title":"Surg Infect"},{"key":"10.1016\/j.jiac.2018.10.012_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A\u00a0Review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jiac.2018.10.012_bib8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a randomized, Double-blind, Phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.10.012_bib9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2018.10.012_bib10","series-title":"Guideline for the clinical evaluation of antibiotics. PFSB\/ELD Notification No. 1023-3","author":"Pharmaceutical Evaluation Division","year":"2017"},{"key":"10.1016\/j.jiac.2018.10.012_bib11","first-page":"560","article-title":"An open-label multicenter study of tazobactam\/piperacillin in the treatment of patients with intra- abdominal infections","volume":"60","author":"Mikamo","year":"2012","journal-title":"Jpn J Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18304252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18304252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:38Z","timestamp":1761159458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X18304252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1341321X18304252"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2018.10.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}